Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative

Research and development

Amortization of acquired intangibles

Restructuring - operating expenses

Acquisition related expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

ResMed reports robust Q1 performance, eyes margin expansion and partnerships

ResMed's Q1 2023 performance reflects strong revenue growth and a focus on meeting global demand for connected CPAP and APAP devices. The company faces challenges in maintaining gross margins and managing operating expenses but sees opportunities in expanding margins and engaging with new patient segments.

ResMed reports robust Q2 earnings, eyes growth through innovation

ResMed's Q2 2023 earnings call highlighted strong sales growth, increased revenue, and a focus on innovation.
Challenges in supply chain constraints and operating expenses were noted, alongside opportunities in growth drivers.
The company aims to improve lives through respiratory care solutions and digital health innovations by 2025.
ResMed's performance reflects post-COVID awareness of respiratory health importance and customer acceptance of new devices.

ResMed reports robust Q3 performance, eyes global growth opportunities

ResMed's Q3 earnings call highlighted strong financial performance, growth in device revenue and mask sales, and a focus on sustaining profitable growth. The company aims to address challenges in gross margin decline by leveraging opportunities for expansion and reinvestment in growth.

ResMed reports strong Q4 earnings, eyes international growth opportunities

ResMed's Q4 2023 showcased robust financial performance with revenue and earnings growth.
The company's focus on patient care, innovation, and international expansion presents promising opportunities.
Challenges include managing operating expenses, gross margin decline, and pricing dynamics.
Strategic initiatives to improve gross margins and drive revenue growth position ResMed well for the future.

ResMed reports 16% revenue growth in Q1 2024 earnings call

ResMed's Q1 2024 performance showcased revenue growth driven by strong device and mask sales globally.
Despite challenges like margin decline and increased expenses, the company's strategic focus on core business and innovation remains strong.
Opportunities lie in expanding alternative therapies, sustaining growth in devices and masks, and optimizing the SaaS business.
Overall, ResMed is positioned for accelerated profitable growth, prioritizing cost optimization and key initiatives for future success.

ResMed reports strong Q2 earnings, eyes global healthcare expansion

ResMed's Q2 2024 earnings call showcased robust financial performance, strategic priorities in healthcare innovation, and a focus on delivering value through patient care. Despite challenges, the company remains optimistic about growth potential and stakeholder engagement in its mission.

ResMed reports strong Q3 results, eyes global expansion and innovation

ResMed's Q3 earnings call showcased solid financial performance, operational improvements, and a strategic focus on market expansion. With a strong emphasis on innovation and cost discipline, the company is poised for continued growth despite challenges.

ResMed reports robust Q4 growth, eyes digital health opportunities

ResMed's Q4 performance was strong, driven by robust growth and financial stability.
While facing challenges like medication impact and market expansion, opportunities in digital health and partnerships exist.
The company's focus on patient awareness and demand generation remains key to future growth.
Overall, ResMed's strategic initiatives position it well for continued success and innovation.

ResMed excels in Q1 with strong revenue growth and innovation

ResMed's Q1 performance reflects strong revenue growth, product success, and strategic investments.
The company's strengths lie in innovation, supply chain optimization, and proactive growth strategies.
Challenges include competitive pressures, addressing new patient demand, and balancing acquisitions with operational efficiency.
Opportunities abound in digital health, customer partnerships, and expanding patient care pathways.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Sleep apnea sufferers can gain health benefits from PAP (positive airway pressure) treatment in as little as two hours per night, according to a study led by ResMed (NYSE: RMD, ASX: RMD) and presented at the American Thoracic Society's annual International Conference.

Even 2 Hours of PAP Therapy per Night Benefits Sleep Apnea Sufferers: ResMed Study

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced that Jim Hollingshead, President, Sleep and Respiratory Care, has informed ResMed that he has accepted a new position and is leaving the company, effective immediately. Rob Douglas, President and Chief Operating Officer, has been appointed interim President, Sleep and Respiratory Care.

ResMed Announces Leadership Change

Strong demand for sleep and respiratory care devices contributed to ResMed's (RMD) fiscal third-quarter sales performance.

ResMed (RMD) Q3 Earnings Miss Estimates, Margins Decline

ResMed Inc. (NYSE:RMD ) Q3 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Mick Farrell - CEO Brett Sandercock - CFO Rob Douglas - President and COO Jim Hollingshead - President, Sleep & Respiratory Care business David Pendarvis - Chief Administrative Officer and Global General Counsel Conference Call Participants David Low - JPMorgan Gretel Janu - Credit Suisse Lyanne Harrison - Bank of America Saul Hadassin - Barrenjoey Dan Hurren - MST Matthew Mishan - KeyBanc David Bailey - Macquarie Mike Matson - Needham & Company Suraj Kalia - Oppenheimer Operator Hello and welcome to the Q3 Fiscal Year 2022 ResMed Earnings Conference Call. My name is Kevin and I'll be your operator for today's call.

ResMed Inc. (RMD) CEO Mick Farrell on Q3 2022 Results - Earnings Call Transcript

ResMed (RMD) delivered earnings and revenue surprises of -8.33% and 4.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Q3 Earnings and Revenues Lag Estimates

Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at  http://investor.resmed.com

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Brett Sandercock, chief financial officer, will present virtually at the Macquarie Australia Conference on Tuesday, May 3, 2022, beginning at approximately 8:45 a.m. (Australian Eastern Standard Time) via video webcast.

ResMed Announces Participation in the 24th Annual Macquarie Australia Conference

Bio-Rad Laboratories

Labcorp Holdings Inc

Thermo Fisher Scientific

Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.

Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More

SANTA CLARA, Calif.--(BUSINESS WIRE)--Chronic Disease Management Startup Curie AI Secures Seed Funding From ResMed to Advance Respiratory Illness Evaluation and Care

Chronic Disease Management Startup Curie AI Secures Seed Funding From ResMed to Advance Respiratory Illness Evaluation and Care

SAN DIEGO, March 17, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on Tuesday, March 22, 2022, beginning at approximately 1:30 p.m. (Eastern Daylight Time) via webcast.

ResMed Announces Participation in the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum

ResMed's (RMD) robust international performance and an ongoing rebound in device sales instill investor confidence in the stock.

Here's Why You Should Retain ResMed (RMD) Stock for Now

SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- ResMed announced today the results of its 2022 Global Sleep Surveys, in conjunction with National Sleep Awareness Week (March 13-19) and World Sleep Day (March 18). The surveys, conducted in the first quarter of the year,1 asked nearly 25,000 respondents in 12 countries what's keeping them up at night and the results aim to build awareness of the critical role good sleep plays in physical and mental health.

ResMed's Global Sleep Surveys Reveal What's Keeping Us Up at Night; Aim to Bring Awareness to the State of Sleep Health for World Sleep Day

SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will present at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022, beginning at approximately 1:20 p.m. (Eastern Daylight Time) via webcast.

ResMed Announces Participation in the Oppenheimer 32nd Annual Healthcare Conference

We believe that ResMed, a medical equipment company, currently appears to be an attractive pick over Ciena stock, a telecommunications networking equipment and software services company, with a similar revenue base, despite RMD's comparatively higher valuation. RMD stock trades at 10.5x trailing.

Here's Why ResMed Stock Is A Better Pick Over This Networking Equipment Company

ResMed's (RMD) growing focus to expand in the high-growth international markets is an added upside.

ResMed's (RMD) SaaS Arm Strength Aids Growth, Supply Woes Stay

Veeva Systems

Zoetis

The key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions. The post 3 Beaten-Down Growth Stocks With More Than 50% Upside Potential appeared first on InvestorPlace.

3 Beaten-Down Growth Stocks With More Than 50% Upside Potential

SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the Citi Healthcare Conference on Wednesday, February 23, 2022, beginning at approximately 12:30 p.m. (Eastern Standard Time) via webcast.

ResMed Announces Participation in the Citi Healthcare Conference

Investors are optimistic about ResMed (RMD) on increased demand for sleep and respiratory care devices on steady recovery of markets from COVID-19 impacts.

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the appointment of Urvashi Tyagi as chief technology officer (CTO), effective today.

ResMed Welcomes Urvashi Tyagi as New Chief Technology Officer

ResMed's (RMD) Q2 earnings meet estimates, with robust demand for sleep and respiratory care devices driving the top line.

ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates

ResMed Inc (NYSE: RMD) revealed a 13% Y/Y jump in Q2 FY22 revenue to $894.9 million, missing the consensus of $935.25 million. The growth was below analyst expectations as the business faced increased freight and production costs.

ResMed Q2 Earnings Highlights: Supply Chain Constraints, Unlimited Demand Due To Competitor Recall

ResMed Inc. (RMD) CEO Mick Farrell on Q2 2022 Results - Earnings Call Transcript

ResMed (RMD) delivered earnings and revenue surprises of 0% and 3.92%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Q2 Earnings Meet Estimates

Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2022

ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

News for ResMed Stock (RMD)